Open Heart · 2014 · 19 citations · 28 references
MedicinePharmacotherapySurgeryAmputation RehabilitationClinical PharmacologyVascular SurgeryAntiplatelet TherapyEndovascular SurgeryLower Extremity RevascularizationOutcome AssessmentAntiplatelet DrugsEndovascular Intervention CareFemoro-femoral BypassFemoropopliteal DiseaseFemoropopliteal InterventionFemoropopliteal RevascularizationInfrapopliteal InterventionTarget Lesion Revascularization
BACKGROUND: Cilostazol is an oral antiplatelet agent currently indicated for treatment of intermittent claudication. There is evidence that cilostazol may reduce femoropopliteal restenosis after percutaneous endovascular intervention. METHODS: We searched PubMed, Scopus and Cochrane databases from 1966 through September 2013 for randomised controlled trials (RCTs) evaluating the addition of cilostazol to standard care in patients receiving femoropopliteal endovascular treatment. Restenosis, target lesion revascularisation and combined adverse outcomes (death, revascularisation and amputation) within 1-2 years postprocedure were evaluated. RESULTS: Of 205 articles, three RCTs were included in the analysis. The pooled data provided a total of 396 patients, 195 of whom received cilostazol. When compared to standard medical therapy alone, cilostazol significantly reduced the risk of restenosis (risk difference -0.20; 95% CI -0.29 to -0.11; p<0.0001; number needed to treat 5), target lesion revascularisation (risk difference -0.17; 95% CI -0.25 to -0.09; p<0.0001; number needed to treat 6). Death and amputation were not different in between groups. CONCLUSIONS AND LIMITATION: Cilostazol significantly increases femoropopliteal patency and decreases adverse outcomes in percutaneous endovascular intervention. However, further RCTs are needed because of limited sample size; this meta-analysis represents the best current evidence.
28
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 83.3K citations · Full text
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff et al. · PubMed · 2009 · 45.1K citations · Full text
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Lars Norgren, William R. Hiatt, John Dormandy et al. · Journal of Vascular Surgery · 2007 · 8.2K citations · Full text
Medicine, Cardiology, Surgery +15